Sachin Kumar Deshmukh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sachin Kumar Deshmukh has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth I. Heath
Mayo Clinic Rochester Minnesota USA
30 shared publications - Rana R. McKay
Division of Medical Oncology University of California, San Diego Moores Cancer Center San Diego California USA
30 shared publications - Chadi Nabhan
Department of Medical Affairs, CarisLifeSciences, Irving, Texas
29 shared publications - Sharon Wu
Caris Life Sciences, Phoenix, Arizona
29 shared publications - Alejandro Recio-Boiles
Department of Medicine, Hematology and Medical Oncology, The University of Arizona Comprehensive Cancer Center, Tucson, Arizona
19 shared publications - Alex Farrell
Caris Life Sciences Phoenix Arizona USA
19 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (10) , e70707
Molecular and Immune Features of Metastatic Prostate Cancer in Hispanic and Non‐Hispanic American Men
Background: Prostate cancer (PCa) is the most common solid tumor in American men, with persistent ethnic disparities, particularly among Hispanic American (HA) men. The tumor microenvironment (TME) and tumor genomics may contribute to disease progression but remain undercharacterized in HA populations. Methods: We conducted a retrospective exploratory analysis of 83 patients with treatment‐naïve metastatic hormone‐sensitive prostate cancer who underwent next‐generation sequencing (NGS). Tumor genomic alterations, immune profiles, pathway activity, and clinical characteristics were compared between HA and non‐Hispanic White (NHW) patients. Results: Compared with NHW patients, HA patients presented with higher PSA levels (111.5 vs. 52.6 ng/mL, p = 0.02), and more advanced disease, including T4 tumors (41% vs. 14%, p = 0.01) and visceral metastases (41% vs. 16%, p = 0.04). Pathway analyses identified increased KRAS (FDR = 0.02), Hedgehog (FDR = 0.04), and NOTCH (FDR = 0.07) signaling in HA tumors. HA tumors exhibited higher expression of stem cell markers ( ALDH1A1 , ALDH1A2 , PROM1 ) and immunoinhibitory genes ( PDCD1LG2 , FOXP3 ) (all p < 0.05), along with increased infiltration of M1 macrophages (0.72% vs. 0%) and natural killer (NK) cells (4.84% vs. 3.55%, all p < 0.05 and q < 0.10). HA tumors demonstrated higher expression of genes associated with drug efflux ( ABCC1, ABCB1 ), EMT ( TWIST1, MMP2 ), cell cycle ( CCND2 ), apoptosis inhibition ( BIRC2, XIAP ), and epigenetic regulation ( EP300, TET1, TET2 ) (all p < 0.05 and q < 0.10). Clinically, HA patients initiated therapy earlier (1 vs. 3 months, p ≤ 0.01), had a longer interval to second‐line therapy (20 vs. 11 months, p < 0.05), and had shorter follow‐up (23 vs. 44 months, p = 0.03). Conclusions: HA patients demonstrated differences in genomic alterations, pathway activity, and tumor immune features compared with NHW patients. Given the study's modest sample size and observational design, these findings should be considered hypothesis‐generating and warrant validation in larger prospective cohorts with broader representation of Hispanic American men.
- 25 October 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (10) , e70707
Open AccessMolecular and Immune Features of Metastatic Prostate Cancer in Hispanic and Non‐Hispanic American Men
Background: Prostate cancer (PCa) is the most common solid tumor in American men, with persistent ethnic disparities, particularly among Hispanic American (HA) men. The tumor microenvironment (TME) and tumor genomics may contribute to disease progression but remain undercharacterized in HA populations. Methods: We conducted a retrospective exploratory analysis of 83 patients with treatment‐naïve metastatic hormone‐sensitive prostate cancer who underwent next‐generation sequencing (NGS). Tumor genomic alterations, immune profiles, pathway activity, and clinical characteristics were compared between HA and non‐Hispanic White (NHW) patients. Results: Compared with NHW patients, HA patients presented with higher PSA levels (111.5 vs. 52.6 ng/mL, p = 0.02), and more advanced disease, including T4 tumors (41% vs. 14%, p = 0.01) and visceral metastases (41% vs. 16%, p = 0.04). Pathway analyses identified increased KRAS (FDR = 0.02), Hedgehog (FDR = 0.04), and NOTCH (FDR = 0.07) signaling in HA tumors. HA tumors exhibited higher expression of stem cell markers ( ALDH1A1 , ALDH1A2 , PROM1 ) and immunoinhibitory genes ( PDCD1LG2 , FOXP3 ) (all p < 0.05), along with increased infiltration of M1 macrophages (0.72% vs. 0%) and natural killer (NK) cells (4.84% vs. 3.55%, all p < 0.05 and q < 0.10). HA tumors demonstrated higher expression of genes associated with drug efflux ( ABCC1, ABCB1 ), EMT ( TWIST1, MMP2 ), cell cycle ( CCND2 ), apoptosis inhibition ( BIRC2, XIAP ), and epigenetic regulation ( EP300, TET1, TET2 ) (all p < 0.05 and q < 0.10). Clinically, HA patients initiated therapy earlier (1 vs. 3 months, p ≤ 0.01), had a longer interval to second‐line therapy (20 vs. 11 months, p < 0.05), and had shorter follow‐up (23 vs. 44 months, p = 0.03). Conclusions: HA patients demonstrated differences in genomic alterations, pathway activity, and tumor immune features compared with NHW patients. Given the study's modest sample size and observational design, these findings should be considered hypothesis‐generating and warrant validation in larger prospective cohorts with broader representation of Hispanic American men.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Table S3 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S1 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy
Figure S4 from Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy